Q-Med
1
18M
1
0.03
- Areas of investment
Summary
In 1987 was created Q-Med, which is appeared as Corporate Investor. The main department of described Corporate Investor is located in the Uppsala. The venture was found in Europe in Sweden.
This organization was formed by Manuel Aguero.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - Sweden. Among the various public portfolio startups of the fund, we may underline OxThera Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. Among the most successful fund investment fields, there are Biotechnology, Health Diagnostics.
The fund is constantly included in less than 2 investment rounds annually. The common things for fund are deals in the range of 10 - 50 millions dollars. The top activity for fund was in 2007.
The standard case for the fund is to invest in rounds with 4 partakers. Despite the Q-Med, startups are often financed by SLS Venture, HealthCap. The meaningful sponsors for the fund in investment in the same round are SLS Venture, Industrifonden, HealthCap. In the next rounds fund is usually obtained by Kurma Partners, Idinvest Partners, Ysios Capital.
Investments analytics
Analytics
- Total investments
- 1
- Lead investments
- 0
- Rounds per year
- 0.03
- Investments by industry
- Health Care (1)
- Biotechnology (1)
- Health Diagnostics (1)
- Investments by region
-
- Sweden (1)
- Peak activity year
- 2007
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 16
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.